- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
Dacarbazine is a chemotherapy drug that is administered for the treatment of melanomas, neuroblastoma, and lymphomas. It functions as an alkylating chemotherapy agent, meaning it interferes with DNA reproduction in fast growing cells, thus preventing cell duplication and growth.
This drug is used primarily in the treatment of Hodgkin’s Disease. It is commonly used in conjunction with other chemotherapy drugs in the ABVD treatment regimen (adriamycin, bleomycin, oncovin, dacarbazine).
Dacarbazine is given intravenously. The injection site should be monitored, as the drug is a known irritant. If any signs of inflammation are observed, a doctor should be alerted immediately.
Common side effects include peripheral neuropathy (numbness or tingling in the hands or feet), flu symptoms, and photosensitivity (sensitivity to light).
There is a small chance of developing leukemia as a secondary cancer, so the doctor should monitor patients after treatment stops.